Purpose While much progress has been made in the treatment of breast cancer, cardiac
complications resulting from therapy remain a significant concern. Both anthracyclines and …

Purpose Most women diagnosed with breast cancer are younger than 65 years of age.
Population-based studies on cancer therapy–related cardiotoxicity have focused on older …

Purpose: To evaluate the cardiovascular risk profile of a subset of patients with early-stage
breast cancer treated with adjuvant taxane-anthracycline–containing chemotherapy and/or …

Attempts to carry out clinical trials to improve the treatment of breast cancers, including
chemotherapy and targeted oncologic therapies, often exclude women with baseline …

This prospective study is designed to identify novel imaging (utilizing cardiovascular
magnetic resonance and advance echocardiography) and biochemical markers to detect …

The late-onset cardiotoxic effect of anthracycline is known, however the early detection and
prevention of subclinical myocardial damage has not been fully understood yet. Besides …

Background We examined the longitudinal associations between changes in cardiovascular
biomarkers and cancer therapy–related cardiac dysfunction (CTRCD) in patients with breast …

As the population of breast cancer survivors grows, it has become evident that
chemotherapy has significant cardiotoxic side effects. Echocardiography is a noninvasive …

A majority of modern antitumor pharmaceuticals are accompanied by cardiotoxicity. The
study aims to present practical approaches to stratifying the baseline risk of antitumor …

Introduction Recent advances in chemotherapy have transformed breast cancer from a fatal
disease to a survivable condition. However, many patients who survive their cancer …